Chromosomal instability, commonly abbreviated CIN, is one of the defining hallmarks of cancer. Rather than being a tidy process, it generates a chaotic assortment of copy number variations, structural variants, aneuploidy and, in extreme cases, catastrophic single-event shattering of chromosomes known as chromothripsis. Tumors that accumulate these defects often progress more aggressively, metastasize more readily and respond poorly to immune checkpoint blockade therapies, the blockbuster drugs that have transformed treatment for melanoma, lung cancer and several other malignancies. What has remained less clear is precisely how the individual structural features of unstable genomes relate to the composition and activation state of immune cells infiltrating the tumor. The new study set out to fill that gap by converting messy genomic events into measurable parameters and then testing how each correlates with numerically scored immune status.

The Shizuoka team drew on samples collected through Project HOPE, a multiomics initiative launched by the Shizuoka Cancer Center in 2014 with ethical approval from the center’s Institutional Review Board and informed consent from all participants. For each of the 394 tumors, the researchers performed whole genome sequencing to inventory structural changes and gene expression profiling to capture the transcriptional fingerprint of the tumor and its microenvironment. From the sequencing data they derived a battery of CIN-related metrics: tumor mutation burden, structural variant burden, microsatellite instability score, ploidy, homologous recombination deficiency score, chromothripsis score and whole genome duplication score. Each of these numbers describes a different way a cancer genome can go wrong, from point-level mutational load to wholesale doubling of the entire chromosomal complement.

The analytical centerpiece of the study was TIMMUSCORA, a tumor immune status scoring algorithm the same group had previously developed. Rather than relying on a single marker such as the presence or absence of T cells, the algorithm integrates multiple transcriptional signals to assign each tumor a numerical score that spans the full range of immune states, from robust activation to deep suppression. When the team mapped their CIN-related parameters against these scores, a consistent pattern emerged. Most of the CIN-related parameters were associated with low TIMMUSCORA scores, indicating an immunosuppressive microenvironment. In other words, the more structurally deranged the genome, the colder and less immunologically active the tumor tended to be.

To understand what was happening at the level of individual genes and cell types, the investigators compared differentially expressed genes between tumors that carried whole genome duplication or chromothripsis and tumors that did not. Whole genome duplication, a catastrophic event in which a cell duplicates its entire genome, occurs frequently in solid tumors and is thought to fuel tolerance of aneuploidy. Chromothripsis, meanwhile, pulverizes one or more chromosomes in a single catastrophic episode, scattering fragments that are haphazardly reassembled. The comparison revealed that tumors harboring either event showed down-regulation of B cell markers and down-regulation of myeloid cell markers, suggesting that key populations of adaptive and innate immune cells are depleted or functionally muted in these genomically chaotic tumors. Intriguingly, the same tumors also displayed up-regulation of the NKG2D gene, which encodes a receptor on natural killer cells and cytotoxic T lymphocytes that recognizes stress-induced ligands on malignant cells.

The up-regulation of NKG2D is a particularly interesting signal because it hints at a counter-current within an otherwise immunosuppressive landscape. Natural killer cells represent the innate arm of anti-tumor immunity, and NKG2D is one of their principal activating receptors. Its elevated expression in chromothripsis-positive tumors suggests that the innate immune system may be responding to some danger signal generated by genomic catastrophe, even as other components of the immune response are being suppressed. The researchers also observed up-regulation of cancer-testis antigen genes in chromothripsis-positive tumors, a finding with direct translational implications. Cancer-testis antigens, such as the MAGE family of proteins, are normally silent in adult tissues but become re-expressed in tumors, making them attractive targets for therapeutic vaccines and engineered T cell therapies. If chromothripsis reliably flags tumors that expose these antigens, it could serve as a biomarker to select patients for antigen-directed immunotherapies.

Among the novel observations verified in the study, two stand out. First, the team found that TP53 and EGFR mutation events can be associated with whole genome duplication and with low TIMMUSCORA scores, linking two of the most clinically important driver alterations in cancer to a weakened immune microenvironment. TP53, the so-called guardian of the genome, safeguards chromosomal integrity by halting the cell cycle and triggering apoptosis when DNA damage is detected; its loss is a permissive step toward genome chaos. EGFR, a growth factor receptor frequently mutated in lung and other cancers, drives proliferation through signaling pathways that intersect with cell cycle control. The association of mutations in these genes with both genome doubling and immune suppression provides a mechanistic thread connecting driver genetics to the immune phenotype of tumors. Second, the study tied chromothripsis to natural killer cell activation and cancer-testis antigen up-regulation, a pairing that had not been clearly documented before and that suggests chromosomal shattering may paradoxically create vulnerabilities that immunotherapy could exploit.

The technical achievement of the work lies in its integration of two large, complementary data streams. Whole genome sequencing reveals what has structurally happened to the cancer genome, while gene expression profiling reveals how the tumor and its surrounding immune and stromal cells are behaving at the transcriptomic level. By running both through a single quantitative framework, the researchers converted qualitative descriptions such as hot and cold tumors into continuous, comparable scores. This numerical approach, the authors argue, makes TIMMUSCORA a potentially useful tool for evaluating the immune status of CIN-harboring tumors, which have historically been difficult to stratify because their low mutational burdens and suppressed microenvironments place them outside the population of clear responders to existing checkpoint inhibitors.

The clinical context is significant. Immune checkpoint blockade has produced durable responses in a subset of patients, but the fraction of solid cancer patients who benefit remains limited, and tumors with high chromosomal instability are disproportionately represented among non-responders. Understanding the genomic determinants of immune exclusion and suppression is therefore a priority for expanding the reach of immunotherapy. If parameters such as whole genome duplication, homologous recombination deficiency and chromothripsis can be routinely measured from tumor sequencing, they could join tumor mutation burden and microsatellite instability as part of a standard immunogenomic profile used to predict which patients are likely to respond to treatment and which may need combination strategies, for example pairing checkpoint blockade with agents that license innate immune cells or with vaccines targeting cancer-testis antigens.

The authors caution that the study’s associations do not yet establish the mechanisms by which chromosomal instability actively suppresses immunity, and they identify this as the central question for future work. Possible avenues include exploring how aneuploid cells alter antigen presentation, how genome doubling changes the release of damage-associated molecular patterns, and how chromothriptic tumors recruit or exclude specific myeloid and lymphoid populations. With the full version of the peer-reviewed, open access article now published, the research community has a validated scoring framework and a richly characterized cohort to build upon. The work was supported by a grant from JAMED and involved clinicians and researchers from seventeen clinical divisions across the Shizuoka Cancer Center Hospital, reflecting a multidisciplinary effort spanning surgical oncology, medical genetics and immunotherapy research. In the longer view, the study adds an important piece to one of oncology’s most consequential puzzles: why some tumors hide in plain sight from the immune system, and how the architecture of a broken genome may hold the key to making them visible again.

Subject of Research: Chromosomal instability and immune suppression in the tumor microenvironment of solid cancers

Article Title: Characterization of the immune status in the tumor microenvironment of solid cancers with chromosomal instability

Article References: Akiyama, Y., Ikeya, T., Iizuka, A., Miyata, H., Maeda, C., Ashizawa, T., Nagashima, T., Urakami, K., Shimoda, Y., Ohshima, K., Shiomi, A., Ohde, Y., Bando, E., Sugiura, T., Mukaigawa, T., Nishimura, S., Hirashima, Y., Mitsuya, K., Yoshikawa, S., … Yamaguchi, K. (2026). Characterization of the immune status in the tumor microenvironment of solid cancers with chromosomal instability. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04547-0

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04547-0

Keywords: Characterization, immune, status, tumor, microenvironment, solid, cancers, chromosomal, instability, scientific research